Riccardo Danielli
Siena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Usefulness of in-vivo reflectance confocal microscopy in patient with nivolumab induced Grover disease.
Journal: Italian journal of dermatology and venereology
Published: August 02, 2022
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients.
Journal: Future oncology (London, England)
Published: February 04, 2021
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
Journal: Journal of endocrinological investigation
Published: August 19, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Journal: European urology
Published: January 03, 2020
Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 23, 2019
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: April 18, 2019
Eruptive porokeratosis under nivolumab adjuvant treatment for melanoma.
Journal: International journal of dermatology
Published: November 22, 2018
Publisher Correction: Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Journal: Nature medicine
Published: October 07, 2018
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy.
Journal: Expert opinion on biological therapy
Published: August 01, 2018
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: January 11, 2018
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.
Journal: Nature medicine
Published: October 11, 2017
Last Updated: 09/26/2026